Related Experiment Video
Updated: Jul 15, 2026
09:43
Measurement of Heme Synthesis Levels in Mammalian Cells
Published on: July 9, 2015
Ceruloplasmin prevents hemostatic disorders during experimental hyperammonemia
M V Osikov1, E V Makarov, L V Krivokhizhina
1Department of Pathophysiology, Chelyabinsk State Medical Academy. mvo2003@list.ru
Bulletin of Experimental Biology and Medicine
|April 7, 2007
Summary
Experimental hyperammonemia in rats caused blood clotting issues and reduced platelet function. Ceruloplasmin treatment normalized coagulation hemostasis and improved platelet activity, suggesting a therapeutic potential for hyperammonemia-induced hemostatic disorders.
Area of Science:
- Biochemistry
- Hematology
- Toxicology
Background:
- Hyperammonemia, a condition of elevated ammonia levels, is associated with significant hemostatic disorders.
- These disorders include coagulopathy and impaired platelet function, posing risks for bleeding and thrombosis.
Purpose of the Study:
- To investigate the hemostatic effects of experimental hyperammonemia in a rat model.
- To evaluate the efficacy of ceruloplasmin in normalizing coagulation and platelet function during hyperammonemia.
Main Methods:
- Induction of experimental hyperammonemia in rats.
- Assessment of blood coagulation parameters, including intrinsic pathway activation.
- Evaluation of platelet function, focusing on secretory processes and aggregation rates.
- Administration of ceruloplasmin at a total dose of 60 mg/kg.
Main Results:
- Experimental hyperammonemia induced coagulopathy and suppressed platelet function in rats.
- Ceruloplasmin treatment effectively normalized coagulation hemostasis.
- Ceruloplasmin improved platelet secretory processes and increased platelet aggregation rates.
Conclusions:
- Hyperammonemia significantly disrupts hemostasis by affecting both coagulation and platelet function.
- Ceruloplasmin demonstrates a potent normalizing effect on hyperammonemia-induced hemostatic abnormalities.
- Ceruloplasmin holds promise as a therapeutic agent for managing bleeding complications associated with hyperammonemia.
Related Concept Videos
01:23Urea Cycle
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...